Intravitreal Anti-Vascular Endothelial Growth Factor Injections for Macular Edema Associated With Central Retinal Vein Occlusion in Patients Age 40 Years or Younger.
Ophthalmic Surg Lasers Imaging Retina
; 50(4): e96-e104, 2019 04 01.
Article
en En
| MEDLINE
| ID: mdl-30998252
ABSTRACT
BACKGROUND AND OBJECTIVE:
To determine the efficacy of anti-vascular endothelial growth factor (VEGF) therapy for macular edema due to central retinal vein occlusion (CRVO) in younger adults. PATIENTS ANDMETHODS:
The outcomes of CRVO patients age 40 years or younger with baseline logarithm of the minimum angle of resolution (logMAR) visual acuity (VA) between 1.30 (20/400 Snellen equivalent) and 0.30 (20/40 Snellen equivalent) and central retinal thickness (CRT) greater than 250 µm were reviewed. VA and CRT were measured at baseline and months 1, 3, 6, and 12.RESULTS:
Seventeen eyes of 17 young CRVO patients were included in this study. The logMAR VA improved significantly from 0.64 (20/87 Snellen equivalent) to 0.14 (20/28 Snellen equivalent) 12 months following treatments (P < .001). The CRT decreased from 619 µm ± 238 µm at baseline to 290 µm ± 34 µm at 12 months (P < .001).CONCLUSION:
Anti-VEGF injections appear to be effective for macular edema regression and vision improvement in younger adults with CRVO over 12 months of follow-up. [Ophthalmic Surg Lasers Imaging Retina. 2019;50e96-e104.].
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Oclusión de la Vena Retiniana
/
Agudeza Visual
/
Edema Macular
/
Bevacizumab
/
Mácula Lútea
Tipo de estudio:
Diagnostic_studies
/
Etiology_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Adolescent
/
Adult
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
Ophthalmic Surg Lasers Imaging Retina
Año:
2019
Tipo del documento:
Article